BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ImmunGene, Inc. and Collaborators Report Positive Results in Pre-clinical Studies of Novel Anti-CD20 Antibody-Interferon Alpha Fusion Protein


6/4/2013 9:04:32 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

THOUSAND OAKS, Calif., June 3, 2013 /PRNewswire/ -- ImmunGene, Inc. today announced that preclinical studies of its novel antiCD20 antibody-interferon alpha fusion protein, IGN002, demonstrated superior antilymphoma activity against numerous cell lines in vitro and against established human xenograft tumors grown in mice. The findings were presented in the Developmental Therapeutics - Immunotherapy poster session on Saturday, June 1, at the 2013 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago (abstract #3024).

"The unique combination of IGN002's potent anti-proliferative and direct apoptosis effects in addition to antibodydependent cellular cytotoxicity and enhanced complement-dependent cytotoxicity has not been seen with any other CD20targeted agent," stated John Timmerman, MD, Associate Professor of Medicine, University of California, Los Angeles (UCLA) Division of HematologyOncology and senior author of the study.

The presentation highlights the rapid progress being made in the development of a new class of anti-cancer biotherapeutics which use antibody-interferon alpha fusion technology. This technology was developed by Sherie Morrison, PhD, Distinguished Professor of Microbiology, Immunology, and Molecular Genetics at UCLA. Part of the pre-clinical research for IGN002 has been done in collaboration with the laboratories of Timmerman and Morrison, who are members of UCLA's Jonsson Comprehensive Cancer Center, and funded by The Leukemia & Lymphoma Society, the UCLA/CalTech Joint Center for Translational Medicine, and the NIH/National Cancer Institute.

"Antibodyfusion proteins are designed to be inactive at therapeutic doses in the bloodstream while highly potent in targeting and killing cancer cells. We believe this approach is likely to spare healthy cells and may reduce many of the known toxic effects of systemically administered cytokines while greatly enhancing the anti-tumor activity of antibodies," said Iqbal Grewal, PhD, DSc, Chief Scientific Officer at ImmunGene. "We are encouraged by the evidence of antitumor activity of IGN002 observed in pre-clinical studies in rituximab-resistant tumor models and are preparing for an IND filing for IGN002 in the second half of 2014."

About IGN002

IGN002, a fusion molecule of anti-CD20 antibody and interferon alpha, two clinically validated anticancer drugs, is designed to to deliver therapeutically effective doses of interferon alpha to CD20-expressing lymphoma cells to exert direct suppression of tumor cell growth and engage multiple anti-tumor immunologic effector mechanisms, leading to substantially improved efficacy while avoiding the systemic toxicity seen with free interferon.

As announced in May 2013, Valor Biotherapeutics, a joint venture between ImmunGene and Caliber Biotherapeutics, has partnered with The Leukemia & Lymphoma Society (LLS) to co-fund the completion of pre-clinical development, manufacturing, and a phase I clinical trial for IGN002.

About ImmunGene, Inc.

ImmunGene is a privately held biotechnology company focused on the development of proprietary antibody-cytokine fusion technology and monoclonal antibody-based therapies to treat cancer, autoimmune disorders, and other diseases. ImmunGene has several programs at various stages of development. ImmunGene is funded by federal government grants including the NIH-SBIR and by private investors including several biotechnology executives. More information can be found at: www.immungene.com.

About Valor Biotherapeutics, LLC

Valor Biotherapeutics, a joint venture between ImmunGene and Caliber Biotherapeutics (www.caliberbio.com), is focused on the clinical development and commercialization of the next generation of monoclonal antibody-based therapeutics to treat cancer. For more information, please visit: www.valorbio.com.

SOURCE ImmunGene, Inc.



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES